Lorenzetti, Razzmatazz University Medical Center, Netherlands discussed on NEJM This Week - Audio Summaries

Automatic TRANSCRIPT

Molecular minimal residual disease and acute myeloid leukemia by moyed cy young in lorenzetti's from the razzmatazz university medical center rotterdam the netherlands patients with acute myeloid leukemia aml often reach complete remission but relapse rates remain high this study involving four hundred eighty two patients with newly diagnosed am l investigated whether targeted molecular monitoring with next generation sequencing could add clinical value for predicting the recurrence of leukemia sequencing was carried out at diagnosis and after induction therapy during complete remission at least one mutation was detected in eighty nine point two percent of patients mutations persisted in fifty one point four percent of those patients during complete remission and were present at various wheel frequencies the detection of persistent mutations which are often present in persons with age related clone tomato polices was not correlated with an increased relapse rate after the exclusion of persistent mutations the detection of molecular minimal residual disease was associated with a significantly higher relapse rate then no detection fifty five point four percent versus thirty one point nine percent as well as with lower rates of relapse free survival thirty six point six percent versus fifty eight point one percent and overall survival forty one point nine percent versus sixty six point one percent a comparison of sequencing with flo saitama tree for the detection of residual disease showed that sequencing had significant additive prognostic value among patients with am l the detection of molecular minimal residual disease during complete remission had significant independent prognostic value with respect to relapse.

Coming up next